Sorafenib Neoadjuvant Therapy in the Treatment of High Risk Renal Cell Carcinoma

Objective: To evaluate the clinical efficacy of sorafenib as preoperative neoadjuvant therapy in patients with high risk renal cell carcinoma (RCC).02/05/2015

Source: Kidney Cancer Association - February 5, 2015 Category: Cancer & Oncology Source Type: news